What Imperagen does
Imperagen combines quantum-mechanics simulation, AI modelling and automated wet-lab testing to optimise industrial enzymes, running iterative design-build-test-learn cycles that the company says can achieve productivity gains of more than 500 times after repeated optimisation. Imperagen serves clients in chemical manufacturing, biopharma, consumer products and industrial biotech, engineering enzymes expressible in E. coli. The company spun out of the Manchester Institute of Biotechnology in 2021, founded by Andrew Currin, Tim Eyes and Andy Almond. Projects typically run four to six months as a service engagement rather than a self-serve product.
Imperagen is a research tool on Falcoscan. AI and quantum-physics platform that engineers better enzymes faster. Falcoscan rates Imperagen with an Opportunity score of 78/100, a Saturation score of 14/100, and a Wrapper-risk score of 15/100. Market signal: rising. Imperagen is founded in 2021, currently at Seed stage. Pricing: Paid.